En naviguant sur notre site vous acceptez l'installation et l'utilisation des cookies sur votre ordinateur. En savoir +

Menu Logo Principal Logo ENVT Logo INP-EI purpan Logo UPS-Tlse3

Toxalim

Zone de texte éditable et éditée et rééditée

Productions

Articles dans des revues internationales à comité de lecture

  • Nom en gras: co-auteur membre de l’équipe

2014

 

  • Concordet D and Servien R. (2014) Individual prediction regions for multivariate longitudinal data with small samples. Accepted in Biometrics.
  • Di Bernardino E, Laloë T and Servien R. (2014) Estimating covariate functions associated to multivariate risks : a level sets approach. Accepted in Metrika.
  • Ferran AA, Toutain PL and Bousquet-Mélou A. (2014) Comparison of the reduction of the antibacterial potency of a fluoroquinolone conferred by a single mutation in the quinolone resistance-detrmining region or by the inoculum size effect. International Journal of Antimicrobial Agents, http://dx.doi.org/10.1016/j.ijantimicag.2014.07.007.
  • Laffont CM, Vandemeulebroecke M, Concordet D. (2014) Multivariate Analysis of Longitudinal Ordinal Data with Mixed Effects Models, with Application to Clinical Outcomes in Osteoarthritis. Accepted in J Am Stat Assoc.
  • Pastor ML, Laffont CM, Gladieff L, Chatelut E and Concordet D. (2014) Model based approach to early predict prolonged high grade neutropenia in carboplatin-treated patients and guide G-CSF prophylactic treatment, Accepted in Pharm Res.
  • Rey JF, Laffont CM, Croubels S, De Backer P,  Zemirline C, Bousquet E, Guyonnet J, Ferran AA, Bousquet-Mélou A and  Toutain PL. (2014) Use of Monte Carlo simulation to examine pharmacodynamic cut-off values of amoxicillin to establish a breakpoint for antimicrobial susceptibility testing in pigs. Am J Vet Res, 75: 124-31.
  • Servien R, Mamy L, Li Z, Rossard V, Latrille E, Bessac F, Patureau D and Benoit P. (2014) TyPol - a New Methodology for Organic Pollutants Clustering based on their Molecular Characteristics and Environmental Behavior. Accepted in Chemosphere.
  • Soraci AL, Amanto F, Tapia MO, de la Torre E and Toutain PL. (2014) Exposure variability of fosfomycin administered to pigs in food or water: Impact of social rank. Res Vet Sci, 96: 153-9.
  • Vasseur M, Laurentie M, Rolland JG, Perrin-Guyomard A, Henri J, Ferran AA, Toutain PL and Bousquet-Mélou A. (2014) Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumonia lung infections but differentially impact the levels of antibiotic resistance in fecal flora. Antimicrob Agents Chemother, 58: 1744-48.
  • Vandenberg LN, Welshons WV, Vom Saal FS, Toutain PL, Myers JP. (2014) Should oral gavage be abandoned in toxicity testing of endocrine disruptors? Environ Health 13: 46.
  • Vom Saal FS, VandeVoort CA, Taylor JA, Welshons WV, Toutain PL, Hunt PA. (2014) Bisphenol A (BPA) pharmacokinetics with daily oral bolus or continuous exposure via silastic capsules in pregnant rhesus monkeys: Relevance for human exposures. Reprod Toxicol [Epub 2014 Feb 25].

 

2013

 

  • Abraham C, Molinari N and Servien R. (2013) Unsupervised clustering of multivariate circular data, Stat Med, 32: 1376-82.
  • Braun JP, Concordet D, Geffre A, Bourges Abella N and Trumel C. (2013) Confidence intervals of reference limits in small reference sample groups, Vet Clin Pathol, 42: 395-8.
  • Corbel T, Gayrard V, Viguie C, Puel S, Lacroix M.Z, Toutain PL and Picard-Hagen N. (2013) Bisphenol A Disposition in the Sheep Maternal-Placental-Fetal Unit: Mechanisms Determining Fetal Internal Exposure, Biol Reprod, 89: 1-9.
  • David I, Elsen JM and Concordet D. (2013) CLIP Test: a new fast, simple and powerful method to distinguish between linked or pleiotropic quantitative trait loci in linkage disequilibria analysis, Heredity (Edinb), 110: 232-8.
  • Diallo AA, Brugere H, Kerouredan M, Dupouy V, Toutain PL, Bousquet-Melou A, Oswald E. and Bibbal D. (2013) Persistence and prevalence of pathogenic and extended-spectrum beta-lactamase-producing Escherichia coli in municipal wastewater treatment plant receiving slaughterhouse wastewater, Water Res, 47: 4719-29.
  • Ferran AA, Bibbal D, Pellet T, Laurentie M, Gicquel-Bruneau M, Sanders P, Schneider M, Toutain PL and Bousquet-Melou A. (2013) Pharmacokinetic/pharmacodynamic assessment of the effects of parenteral administration of a fluoroquinolone on the intestinal microbiota: Comparison of bactericidal activity at the gut versus the systemic level in a pig model. Int J Antimicrob Ag 42: 429-35.
  • Gayrard V, Lacroix MZ, Collet SH, Viguie C, Bousquet-Melou A, Toutain PL and Picard-Hagen N (2013) High Bioavailability of Bisphenol A from Sublingual Exposure. Environ Health Perspect, 121: 951-56.
  • Gayrard V, Lacroix MZ, Collet SH, Viguie C, Bousquet-Melou A, Toutain PL and Picard-Hagen N. (2013) Interpreting bisphenol A absorption in the canine oral cavity: Gayrard et Al. Respond, Environ Health Perspect, 121(11-12): A323-4.
  • Jeunesse EC*, Schneider M, Woehrle F, Faucher M, Lefebvre HP and Toutain PL (2013) Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog, BMC Veterinary Research, 9: 250. (*team member when studies carried on)
  • Laloe T and Servien R. (2013) Nonparametric estimation of regression level sets using kernel plug-in estimator. J Korean Stat Soc, 42: 301-11.
  • Pastor ML, Laffont CM, Gladieff L, Schmitt A, Chatelut E and Concordet D. (2013) Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients. Pharm Res, 30: 2795-807.
  • Regnier A*, Laroute V*, Gautier-Bouchardon A, Gayrard V, Picard-Hagen N and Toutain PL. (2013) Florfenicol concentrations in ovine tear fluid following intramuscular and subcutaneous administration and comparison with the minimum inhibitory concentrations against mycoplasmal strains potentially involved in infectious keratoconjunctivitis, Am J Vet Res 74: 268-74. (*team member when studies carried on)
  • Toutain PL. (2013) Control of medication in horses: Detection time, withdrawal time and beyond. Vet J, 198: 305-6.
  • Viguie C, Collet SH, Gayrard V, Picard-Hagen N, Puel S, Roques BB, Toutain PL and Lacroix MZ. (2013) Maternal and fetal exposure to Bisphenol A is associated with alterations of thyroid function in pregnant ewes and their newborn lambs. Endocrinology, 154: 521-8.

2012

  • Baynes R, Riviere J, Franz T, Monteiro-Riviere N, Lehman P, Peyrou M and Toutain PL. (2012) Challenges obtaining a biowaiver for topical veterinary dosage forms, J Vet Pharmacol Ther, 35 Suppl 1: 103-14.
  • Chetboul V, Daste T, Gouni V, Concordet D, Trehiou-Sechi E, Serres F, Pouchelon JL, Germain CA, Layssol-Lamour C and Lefebvre HP. (2012) Renal resistive index in 55 dogs with degenerative mitral valve disease, J Vet Intern Med, 26: 101-8.
  • Collignon CM, Heiene R, Queau Y, Reynolds BS, Craig AJ, Concordet D, Harran NX, Risoen U, Balouka D, Faucher MR, Eliassen KA, Biourge V and Lefebvre HP. (2012) Comparison of pharmacokinetic variables for creatinine and iohexol in dogs with various degrees of renal function, Am J Vet Res, 73: 1841-7.
  • Domingos MC, Medaille C, Concordet D and Briend-Marchal A. (2012) Is it possible to use expired tubes for routine biochemical analysis in dogs?, Vet Clin Pathol, 41: 266-71.
  • Geffré A, Concordet D, Braun JP, Trumel C. (2012) Reference Value Advisor: a new freeware set of macroinstructions to calculate reference intervals with Microsoft Excel. Vet Clin Pathol, 40:107-12.
  • Hunter RP, Lees P, Concordet D and Toutain PL. (2012) Establishing bioequivalence of veterinary premixes (Type A medicated articles), J Vet Pharmacol Ther, 35: 53-63.
  • Khadra A, Pinelli E, Lacroix MZ, Bousquet-Melou A, Hamdi H, Merlina G, Guiresse M and Hafidi M. (2012) Assessment of the genotoxicity of quinolone and fluoroquinolones contaminated soil with the Vicia faba micronucleus test, Ecotoxicology and Environmental Safety, 76: 187-192.
  • Lees P, Hunter RP, Reeves PT and Toutain PL. (2012) Pharmacokinetics and pharmacodynamics of stereoisomeric drugs with particular reference to bioequivalence determination, J Vet Pharmacol Ther, 35: 17-30.
  • Lees P and Toutain PL. (2012) The role of pharmacokinetics in veterinary drug residues. Drug Test Anal, Suppl 1: 34-9.
  • Pelligand L, King JN, Toutain PL, Elliott J and Lees P. (2012) Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation, J Vet Pharmacol Ther, 35: 19-32.
  • Taylor JA, vom Saal FS, Welshons WV, Drury B, Rottinghaus G, Hunt PA, Toutain PL and Laffont CM. (2012) Bisphenol A in Thermal Paper Receipts: An Opportunity for Evidence-Based Prevention Response, Environ Health Perspect, 120: A15.
  • Toutain PL, Modric S, Bousquet-Melou A, Sallovitz JM and Lanusse C. (2012) Should licking behavior be considered in the bioavailability evaluation of transdermal products? J Vet Pharmacol Ther, 35 Suppl 1: 39-43.

 

2011

  • Bertrand J, Laffont CM, Mentré F, Chenel M, Comets E. (2011) Development of a Complex Parent-Metabolite Joint Population Pharmacokinetic Model. AAPS J, 13, 390-404. [IF 2010=3.942; IF 5-Year=5.265; PHARMACOLOGY & PHARMACY, Q1] ()
  • Bousquet-Melou A., Jacquiet P., Hoste H., Clement J., Bergeaud J-P., Alvinerie M., Toutain P.-L. (2011) Licking behaviour induces partial anthelmintic efficacy of ivermectin pour-on formulation in untreated cattle.Int. J. Parasitol., 41, 563-569. [IF 2010=3.822; IF 5-Year=3.938; PARASITOLOGY, Q1]
  • Ferran A.A., Toutain P.L., Bousquet-Melou A. (2011) Impact of early versus later fluoroquinolone treatment on the clinical, microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infection. Vet. Microbiol., 148, 292-297. [IF 2010=3.256; IF 5-Year=3.121; VETERINARY SCIENCES, Q1]
  • Fosse TK, Toutain PL, Spadavecchia C, Haga HA, Horsberg TE, Ranheim B. (2011) Ketoprofen in piglets: enantioselective pharmacokinetics, pharmacodynamics and PK/PD modelling. J. Vet. Pharmacol. Ther., 34, 338-349. [IF 2010=1.675; IF 5-Year=1.701; VETERINARY SCIENCES, Q1] ()
  • Jeunesse EC,Bargues IA, Toutain CE, Lacroix MZ, Letellier IM, Giraudel JM, Toutain PL. (2011) Paw inflammation model in dogs for preclinical PK/PD investigations of non steroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther., 338, 548-558. [IF 2010=4.017; IF 5-Year=4.089; PHARMACOLOGY & PHARMACY, Q1]
  • Kahdra A, Pinelli E, Lacroix M, Bousquet-Mélou A, Merlina G, Revel JC, Hafidi M. Assessment of the genotoxicity of Quinolones-contaminated soil with the Vicia faba micronucleus test. Ecotox. Environ. Safe. In press. [IF 2010=2.340; IF 5-Year=2.718; TOXICOLOGY , Q2]
  • Khachman D, Conil JM, Georges B, Saivin S, Houin G, Toutain PL, Laffont CM (2011). Optimising ciprofloxacin dosing in intensive care patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations. J. Antimicrob. Chemother., 66, 1789-1809 [IF 2010=4.659 ; IF 5-Year=4.480 ; PHARMACOLOGY & PHARMACY]
  • Kieken F., Pinel G., Antignac J.P., Paris A.C., Garcia P., Popot M.A., Grall M., Mercadier V., Toutain P.L., Bonnaire Y., Le Bizec B. (2011) Generation and processing of urinary and plasmatic metabolomic fingerprints to reveal an illegal administration of recombinant equine growth hormone from LC-HRMS measurements. Metabolomics, 7, 84-93. [IF 2010=3.608; IF 5-Year=3.637; ENDOCRINOLOGY & METABOLISM, Q2]
  • Lacroix MZ, Puel S, Collet SH, Corbel T, Picard-Hagen N, Toutain P.L.Viguié C, Gayrard V. (2011) Simultaneous quantification of bisphenol A and its glucuronide metabolite (BPA-G) in plasma and urine: Applicability to toxicokinetic investigations. Talanta, 85, 2053-2059. [IF 2010=3.722; IF 5-Year=3.487; CHEMISTRY, ANALYTICAL, Q1] (►)
  • Laffont C.M., Concordet D. (2011) A New Exact Test for the Evaluation of Population Pharmacokinetic and/or Pharmacodynamic Models Using Random Projections. Pharm. Res., 28, 1948-1962. [IF 2010=4.456; IF 5-Year=4.546; PHARMACOLOGY & PHARMACY, Q1] ()
  • Mathon DH, Palierne S, Meynaud-Collard P, Layssol-Lamour C, Dulaurent-Ferrieres A, Colson A, Lacroix M, Bousquet-Melou A, Delverdier M, Autefage A. (2011) Laparoscopic-assisted colopexy and sterilization in male dogs: short-term results and physiologic consequences. Vet. Surg., 40, 500-508. [IF 2010=1.437; IF 5-Year=1.733; VETERINARY SCIENCES, Q1] ()
  • Pelligand L, King JN, Toutain PL, Elliott J, Lees P. (2011) Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation. J Vet Pharmacol Ther., in press. [IF 2010=1.675; IF 5-Year=1.701; VETERINARY SCIENCES, Q1] ()
  • Regnier A, Andreoletti O, Albaric O, Cayez Gruson D, Schelcher F, Toutain PL. (2011) Clinical, electroretinographic and histomorphometric evaluation of the retina in sheep with natural scrapie. BMC Vet Res., 7, 25. [IF 2010=2.371; IF 5-Year= ; VETERINARY SCIENCES, Q1] ()
  • Sidhu PK, Landoni MF, Aliabadi MH, Toutain PL, Lees P. (2011) Pharmacokinetic and pharmacodynamic modelling of marbofloxacin administered alone and in combination with tolfenamic acid in calves. J. Vet. Pharmacol. Ther., 34, 376-387. [IF 2010=1.675; IF 5-Year=1.701; VETERINARY SCIENCES, Q1 ] ()
  • Sieli PT, Jašarević E, Warzak DA, Mao J, Ellersieck MR, Liao C, Kannan K, Collet SH, Toutain PL, Vom Saal FS, Rosenfeld CS. (2011) Comparison of Serum Bisphenol A Concentrations in Mice Exposed to Bisphenol A through the Diet Versus Oral Bolus Exposure. Environ. Health Perspect., 119, 1260-1265. [IF 2010=6.087; IF 5-Year=7. 203; ENVIRONMENTAL SCIENCES, Q1] ()
  • Taylor JA, Vom Saal FS, Welshons WV, Drury B, Rottinghaus G, Hunt PA, Toutain PL, Laffont CM, Vandevoort CA. (2011) Similarity of bisphenol a pharmacokinetics in rhesus monkeys and mice: relevance for human exposure. Environ. Health Perspect.,119, 422-430. [IF 2010=6.087; IF 5-Year=7. 203 ; ENVIRONMENTAL SCIENCES, Q1] ()

2010

  • AuthiéE., Garcia P., Popot M.A., ToutainP.L., DoucetM.Y. (2010) Effect of an endurance-like exercise on the disposition and detection time of phenylbutazone and dexamethasone in the horse: application to medication control, Equine Vet J, 42(3): 240-247. [IF 2009=1.837; IF 5-Year=2.310]
  • Cattiaux P., Chafai D. and Motsch S. (2010) Asymptotic analysis and diffusion limit of the Persistent Turning Walker Model, Asymptotic Analysis, 67(1-2): 17-31.
  • ChafaïD., Malrieu F. (2010) On fine properties of mixtures with respect to concentration of measure and Sobolev type inequalities, Ann. Inst. Henri Poincare,46, 72-96.(* : membre de l’équipe jusqu’en septembre 2009)
  • ChafaïD., Malrieu F., Paroux K. (2010) On the long time behaviour of the TCP window size process, Stoch. Proc. Appl., 120, 1518-1534.
  • Ferran A.A., Toutain P.L., Bousquet-Melou A. (2010) Impact of early versus later fluoroquinolone treatment on the clinical, microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infection. Vet. Microbiol., 148, 292-297. [IF 2009=2.874; IF 5-Year=2.937]
  • Kesteman A.S., Perrin-Guyomard A., Laurentie M., Sanders P., Toutain P.L., Bousquet-MelouA. (2010) Emergence of resistant Klebsiella pneumoniae in the intestinal tract during successful treatment of Klebsiella pneumoniae lung infection in rats, Antimicrob Agents Chemother, 54(7): 2960-4. [IF 2009=4.802; IF 5-Year=4.819]
  • Schmitt A., Gladieff L., Laffont C.M., Evrard A., Boyer J.C., Lansiaux A., Bobin-Dubigeon C., Etienne-Grimaldi M.C , Boisdron-Celle M., Mousseau M., Pinguet F., Floquet A., Billaud E.M., Durdux C., Le Guellec C., Mazières J., Lafont T., Ollivier F., Concordet D. and Chatelut E. (2010) Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic Exposure, J. Clin. Oncol. 28(30): 4568-4574. [IF 2009=17.763; IF 5-Year=15.969]
  • Toutain P.L. (2010) How to extrapolate a withdrawal time from an EHSLC published detection time: a Monte Carlo simulation appraisal, Equine Vet J, 42(3): 248-254. [IF 2009=1.837; IF 5-Year=2.310]
  • Toutain P.L. (2010) Veterinary medicines and competition animals: the question of medication versus doping control, Handb Exp Pharmacol (199): 315-39.
  • Toutain P.L., Ferran A. and Bousquet-Melou A. (2010) Species differences in pharmacokinetics and pharmacodynamics, Handb Exp Pharmacol (199): 19-48.

2009

  • Antic J, Laffont C, Chafaï D, Concordet D (2009). Comparison of nonparametric methods in nonlinear mixed effects models, Comput. Stat. Data Anal. 53: 642-656. (5-Y IF : 1,228, IF : 1,126)
  • Bibbal D, Dupouy V, Prere MF, Toutain PL, Bousquet-Mélou A (2009). Relatedness of Escherichia Coli with Different Susceptibility Phenotypes Isolated from Swine Feces during Ampicillin Treatment, Appl. Environ. Microbiol. 75, 2999-3006. (5-Y IF : 4,535, IF : 3,801)
  • Chafaï D (2009). Aspects of large random Markov kernels. Stochastics81:415-429.
  • Chafaï D, Concordet D (2009). A new method for the estimation of variance matrix with prescribed zeros in nonlinear mixed effects models, Stat. Comput. 19: 129-138 (5-Y IF: 1,819, IF : 1,371)
  • Toutain PL, Bousquet-Mélou A (2009). New antibiotics in orphan food-producing animals: What is the responsibility of a Journal regarding good veterinary practice?, Vet. J. 179(2): 155-7. Guest Editorial (5-Y IF : 1,978, IF : 1,802)
  • Chafaï D,Concordet D (2009). Confidence region for the multinomial parameter with small sample size, J. Am. Stat. Assoc. 104, 1071-1079. (5-Y IF : 3,462, IF : 2,394)
  • Concordet D, Geffre A, Braun JP, Trumel C (2009). A new approach for the determination of reference intervals from hospital-based data, Clin. Chim. Acta., 405(1-2): 43-48 (5-Y IF: 2,806, IF : 2,960)
  • Ferran AA, Kesteman AS, Toutain PL, Bousquet-MelouA (2009). Pharmacokinetic /pharmaco-dynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model.Antimicrob. Agents Chemother., 53, 3384-3390. (5-Y IF : 4,537, IF : 4,716)
  • Giraudel* JM, King JN, Jeunesse EC, Lees P, ToutainPL (2009). Use of a pharmacokinetic/ pharmacodynamic approach in the cat to determine a dosage regimen for the COX-2 selective drug robenacoxib, J. Vet. Pharmacol. Ther. 32(1): 18-30. (5-Y IF : 1,666, IF : 1,581) (*doctorant de l’UMR de 1999 à 2004)
  • Giraudel* JM, Toutain PL, King JN, Lees P (2009). Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib, J. Vet. Pharmacol. Ther. 32(1): 31-40. (5-Y IF : 1,666, IF : 1,581) (*doctorant de l’UMR de 1999 à 2004)
  • Kesteman AS, Ferran AA, Perrin-Guyomard A, Laurentie M, Sanders P, Toutain PL, Bousquet-Melou A. (2009) Influence of Inoculum Size and Marbofloxacin Plasma Exposure on the Amplification of Resistant Subpopulations of Klebsiella pneumoniae in a Rat Lung Infection Model.Antimicrob. Agents Chemother. 53(11): 4740-4748. (5-Y IF : 4,537, IF : 4,716)
  • King JN, Dawson J, Esser RE, Fujimoto R, Kimble EF, Maniara W, Marshall PJ, O'Byrne L, Quadros E, Toutain PL, Lees P (2009). Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2, J. Vet. Pharmacol. Ther. 32(1): 1-17. (5-Y IF : 1,666, IF : 1,581)

2008

  • Bakry D, Baudouin F, Bonnefont M, Chafaï D (2008). On gradient bounds for the heat kernel on the Heisenberg group, J. Funct. Anal. 55: 1905-1938 (5-Y IF: 1,181, IF : 1,063)
  • Chafaï D, Concordet D (2008). Explicit formulas for a continuous stochastic maturation model: Application to anticancer drug pharmacokinetics/pharmacodynamics, Stoch. Models 24: 376-400 (5-Y IF: 0,892, IF : 0,642, Statistics & Probability 70/92, Q4)
  • Concordet D, Vergez F, Trumel C, Diquelou A, Lanore D, Le Garreres A, Pages JP, Pechereau D, Medaille C, Braun JP (2008). A multicentric retrospective study on serum/plasma urea and creatinine concentrations in dogs, Vet. Clin. Path. 37(1): 96-103 (5-Y IF: 1,275, IF : 0,917)
  • Lafforgue G, Arellano C, Vachoux C, Woodley J, Philibert C, Dupouy V, Bousquet-Mélou A, Gandia P, Houin G (2008). Oral absorption of ampicillin: role of paracellular route vs. PepT1 transporter, Fundam. Clin. Pharmacol. 22(2): 189-201 (5-Y IF : 2;165, IF : 2,109)
  • Palierne S, Mathon D, Asimus E , Concordet D, Meynaud-Collard P, Autefage A (2008). Segmentation of the canine population in different femoral morphological groups, Res. Vet. Sci. 85(3): 407-17 (5-Y IF: 1,514, IF : 1,384, Veterinary Science 35/134, Q2)
  • Pasmans F, Baert K, Martel A, Bousquet-Mélou A, Lanckriet R, De Boever S, Van Immerseel F, Eeckhaut V, de Backer P, Haesebrouck F (2008). Induction of the Carrier State in Pigeons Infected with Salmonella enterica Subspecies enterica Serovar Typhimurium PT99 by Treatment with Florfenicol: a Matter of Pharmacokinetics, Antimicrob. Agents Chemother. 52(3): 954-61 (5-Y IF : 4,537, IF : 4,716)
  • Regnier A, Schneider M, Concordet D, Toutain PL (2008). Intraocular pharmacokinetics of intravenously administered marbofloxacin in rabbits with experimentally induced acute endophthalmitis, Am. J. Vet. Res. 69(3): 410-5 (5-Y IF : 1,432, IF : 1,280)
  • Vandenbroucke V, Bousquet-Melou A, de Backer P, Croubels S (2008). Pharmacokinetics of eight anticoagulant rodenticides in mice after single oral administration, J. Vet. Pharmacol. Ther. 31: 437-445 (5-Y IF : 1,666, IF : 1,581)

2007

  • Bibbal D, Dupouy V, Ferre JP, Toutain PL, Fayet O, Prere MF, Bousquet-Mélou A (2007). Impact of three ampicillin dosage regimens on selection of ampicillin resistance in Enterobacteriaceae and excretion of blaTEM genes in swine feces, Appl. Environ. Microbiol. 73(15): 4785-90 (5-Y IF : 4,535, IF : 3,801)
  • Chafaï D, Concordet D (2007). On the strong consistency of asymptotic M-estimators, J. Stat. Plan. Infer. 137: 2774-2783.
  • Ferran A, Dupouy V, Toutain PL, Bousquet-Mélou A (2007). Influence of Inoculum Size on the Selection of Resistant Mutants of Escherichia coli in Relation to Mutant Prevention Concentrations of Marbofloxacin, Antimicrob. Agents Chemother. 51(11): 4163-6 (5-Y IF : 4,537, IF : 4,716)
  • Ferre PJ, Liaubet L, Concordet D, SanCristobal M, Uro-Coste E, Tosser-Klopp G, Bonnet A, Toutain PL, Hatey F, Lefebvre HP (2007). Longitudinal analysis of gene expression in porcine skeletal muscle after post-injection local injury, Pharm. Res. 24(8): 1480-9 (5-Y IF: 3,831, IF : 4,024)
  • Jeunesse E, Woehrle F, Schneider M, LefebvreHP (2007). Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs, J. Vet. Cardiol. 9: 63-68.
  • Lallemand E, Lespine A, Alvinerie M, Bousquet-Melou A, ToutainPL (2007). Estimation of absolute oral bioavailability of moxidectin in dogs using a semi-simultaneous method: influence of lipid co-administration, J. Vet. Pharmacol. Ther. 30(5): 375-80 (5-Y IF : 1,666, IF : 1,581)
  • Lefebvre HP, Brown SA, Chetboul V, JN King, Pouchelon JL, Toutain PL (2007). Angiotensin-converting enzyme inhibitors in veterinary medicine, Curr. Pharm. Design 13(13): 1347-61 (5-Y IF: 4,159, IF : 4,399)
  • Popot MA, Menaut L, Boyer S, Bonnaire Y, Toutain PL (2007). Spurious urine excretion drug profile in the horse due to bedding contamination and drug recycling: the case of meclofenamic acid, J. Vet. Pharmacol. Ther. 30(2): 179-84 (5-Y IF : 1,666, IF : 1,581)
  • Toutain PL, Bousquet-Mélou A, Martinez M (2007). AUC/MIC: a PK/PD index for antibiotics with a time dimension or simply a dimensionless scoring factor?, J. Antimicrob. Chemother. 60(6) : 1185-8 (5-Y IF : 4,219, IF : 4,328)

2006

  • Bousquet-Melou A, Formentini* E, Picard-Hagen N, Delage L, Laroute V, Toutain PL (2006). The Adrenocorticotropin Stimulation Test: Contribution of a Physiologically Based Model Developed in Horse for Its Interpretation in Different Pathophysiological Situations Encountered in Man, Endocrinology 147(9): 4281-4291 (5-Y IF : 5,255 IF : 4,945) (* post-doc étranger dans l’UMR de 2000 à 2002)
  • Chafaï D (2006). Binomial-Poisson entropic inequalities and the M/M/infinity queue, ESAIM/P&S 10: 317-339.
  • Chafaï D, Loubes JM (2006). On nonparametric maximum likelihood for a class of stochastic inverse problems, Stat. Probabil. Lett. 76: 1225-1237 (5-Y IF: 0,530, IF : 0,445)
  • Craig AJ, Seguela J, Queau Y, Murgier P, Concordet D, Fleeman LM, Mimouni P, Braun JP, Germain C, LefebvreHP (2006). Redefining the reference interval for plasma creatinine in dogs: Effects of age, gender, body weight, and breed. J. Vet. Intern. Med. 20(3): 740 (5-Y IF: 2,067, IF : 1,885)
  • del Castillo* JR, Laroute V, Pommier P, Zemirline C, Keita A, Concordet D,Toutain PL (2006). Interindividual variability in plasma concentrations after systemic exposure of swine to dietary doxycycline supplied with and without paracetamol: a population pharmacokinetic approach, J. Anim. Sci. 84(11): 3155-66 (5-Y IF: 2,586, IF : 2,123) (* post-doc étranger dans l’UMR de 2001 à 2002)
  • Dupouy VM, Ferre PJ, Uro-Coste E, Lefebvre HP (2006). Time course of COX-1 and COX-2 expression during ischemia-reperfusion in rat skeletal muscle, J. Appl. Physiol. 100(1): 233-9 (5-Y IF: : 3,760, IF : 3,658)
  • Ferre JPLaroute V, Braun JP, Cazaux j, Toutain PL, Lefebvre HP (2006). Simultaneous and minimally invasive assessment of muscle tolerance and bioavailability of different volumes of an intramuscular formulation in the same animals, J. Anim. Sci. 84: 1295-1301 (5-Y IF: 2,586, IF: 2,123)
  • Lees P, Aliabadi FS, Toutain PL (2006). Minimising antimicrobial resistance through rational design of dosing schedules: a role for pre-clinical PK-PD modelling?, J. Vet. Pharmacol. Ther. 29 Suppl 1: 24-6 (5-Y IF : 1,666, IF : 1,581)
  • Lefebvre HP, Jeunesse E, Laroute V, Toutain PL(2006). Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate, J. Vet. Intern. Med. 20(3): 499-507 (5-Y IF: 2,067, IF : 1,885)
  • Lespine A, Chanoit G, Bousquet-Melou A, Lallemand E *, Bassissi FM, Alvinerie M, Toutain PL (2006). Contribution of lymphatic transport to the systemic exposure of orally administered moxidectin in conscious lymph duct-cannulated dogs, Eur. J. Pharm. Sci. 27(1): 37-43 (5-Y IF : 3,601, IF : 3,650, Pharmacology & Pharmacy 46/216, Q1) (*étudiante en thèse vétérinaire dans l’UMR)
  • Peyrou M, Bousquet-Mélou A, Laroute V, Vrins A, Doucet MY (2006). Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first-pass effect and absorbed fraction, J. Vet. Pharmacol. Ther. 29(5) : 337-44 (5-Y IF : 1,666, IF : 1,581)
  • RegnierA, Lemagne C, Ponchet A, Cazalot G, Concordet D, Gelatt KN (2006). Ocular effects of topical 0.03% bimatoprost solution in normotensive feline eyes, Vet. Ophtalmo. 9(1): 39-43 (5-Y IF: 1,486, IF : 1,559)
  • ToutainPL (2006). Population PK and PK/PD investigations and Monte Carlo simulations for a rational dosage regimen, J. Vet. Pharmacol. Ther. 29 Suppl 1: 19-21 (5-Y IF : 1,666, IF : 1,581)
  • Toutain PL, Lees P (2006). The population PK/PD approach for a rational use of anti-infective drugs to minimize resistance, J. Vet. Pharmacol. Ther. 29 Suppl 1: 26-9 (5-Y IF : 1,666, IF : 1,581)

2005

  • Chetboul V, Sampedrano CC, Concordet D, Tissier R, Lamour T, Ginesta J, Gouni V, Nicolle AP, Pouchelon JL, Lefebvre HP (2005). Use of quantitative two-dimensional color tissue Doppler imaging for assessment of left ventricular radial and longitudinal myocardial velocities in dogs, Am. J. Vet. Res. 66(6): 953-61 (5-Y IF: 1,432, IF : 1,280)
  • Chetboul V, Sampedrano CC, Gouni V, Concordet D, Lamour T, Ginesta J, Nicolle AP, Pouchelon JL, Lefebvre HP (2005). Quantitative assessment of regional right ventricular myocardial velocities in awake dogs by Doppler tissue imaging: repeatability, reproducibility, effect of body weight and breed, and comparison with left ventricular myocardial velocities, J. Vet. Intern. Med. 19(6): 837-44 (5-Y IF: 2,067, IF : 1,885)
  • Chetboul V, Tidholm A, Nicolle A, Sampedrano CC, Gouni V, Pouchelon JL, Lefebvre HP, Concordet D (2005). Effects of animal position and number of repeated measurements on selected two-dimensional and M-mode echocardiographic variables in healthy dogs, J. Am. Vet. Med. Assoc. 227(5): 743-7 (5-Y IF : 1,877, IF : 1,773)
  • Crevier-Denoix N, Pourcelot P, Erlinger D, Concordet D, Lagache C, Ricard A, Tavernier L, Denoix JM (2005). Comparison of the Comformation of 20 International Level and the 20 Low Level Jumping Horses Using a 3-D Video Morphometric Measurement Method, J. Vet. Med. C 34(s1): 13-13 (5-Y IF : 1,551, IF : 1,573)
  • Diquelou A, Barbaste C, Gabaig AM, Trumel C, Abella-Bourges N, Guelfi JF, Bousquet-Melou A (2005). Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs, Vet. Clin. Path. 34(3): 237-42 (5-Y IF: 1,275, IF : 0,917)
  • Ferre PJ, Thein E, Raymond-Letron I, Toutain PL, Lefebvre HP (2005). Acute changes in muscle blood flow and concomitant muscle damage after an intramuscular administration, Pharm. Res. 22(3): 405-12 (5-Y IF: 3,831, IF : 4,024)
  • Giraudel JM, Diquelou A, Laroute V, Lees P, ToutainPL(2005). Pharmacokinetic /pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat, Br. J. Pharmacol. 146(5): 642-53 (5-Y IF: 4,214, IF : 4,902)
  • Giraudel JM, Diquelou A, Lees P, Toutain PL (2005). Development and validation of a new model of inflammation in the cat and selection of surrogate endpoints for testing anti-inflammatory drugs, J. Vet. Pharmacol. Ther. 28(3): 275-85 (5-Y IF : 1,666, IF : 1,581)
  • Giraudel JM, Toutain PL, Lees P (2005). Development of in vitro assays for the evaluation of cyclooxygenase inhibitors and predicting selectivity of nonsteroidal anti-inflammatory drugs in cats, Am. J. Vet. Res. 66(4): 700-9 (5-Y IF : 1,432, IF : 1,280)
  • Lefebvre HP and Concordet D (2005). Validation of quantitative endpoints for clinical trials: An emerging challenge, J. Vet. Cardiol. 7: 5-7.
  • Martin PG, Lasserre F, Calleja C, Van Es A, Roulet A, Concordet D, Cantiello M, Barnouin R, Gauthier B and Pineau T (2005). Transcriptional modulations by RXR agonists are only partially subordinated to PPARalpha signaling and attest additional, organ-specific, molecular cross-talks, Gene Expression 12(3): 177-92 (5-Y IF: 1,534, IF : 1,487)

 

Articles de tranfert/vulgarisation

2012

  • Bousquet-Melou A. Léchage entre congénères et antiparasitaires en pour-on. In: Le Point Vétérinaire; 2012 (Parasitologie interne des ruminants):124-126
  • Bousquet-Melou A. Editorial. Nouvelles stratégies en antibiothérapie. In: PratiqueVét; 2012 (supplément):3
  • Bousquet-Melou A., Ferran A., Toutain P.L. Impact du schéma posologique sur la résistance. In: Bulletin des GTV. Paris: Société Nationale des Groupements Techniques Vétérinaires; 2012 (64):29--36
  • Bousquet-Melou A., Toutain P.L. Les interactions impliquant les protéines plasmatiques ne sont plus ce qu'elles étaient. In: La Lettre du Pharmacologue; 2012 (26):44-50
  • Toutain P.L. Paramètres pharmacocinétiques et pharmacodynamiques : ce que tout praticien doit savoir. In: Pratique Vétérinaire; 2012 (47):414-417
  • Toutain P.L., Bousquet-Mélou A. De vieux antibiotiques ou des antibiotiques innovants pour la médecine vétérinaire ? In: Bulletin des GTV. Paris: Société Nationale des Groupements Techniques Vétérinaires; 2012 (64):37-42
  • Toutain P.L., Hugnet C. Les dorsalgies du cheval : quelle est la place des infiltrations ? quel est l'état des preuves ? In: Le Nouveau Praticien Vétérinaire; 2012 (8):7-10

2011

  • Ferran A., Bousquet-Mélou A. (2011) Antibiothérapie : les questions qu’il faut se poser avant toute prescription. Pratique Vétérinaire, 46, 86-88.
  • Ferran A. and Pouliquen H. (2011) Bénéfices/risques de l'utilisation de la céfovécine lors de coryza surinfecté. Le Point Vétérinaire. 319:21.
  • Sanders P., Bousquet-Mélou A., Chauvin C., Toutain P.L. (2011) Utilisation des antibiotiques en élevage et enjeux de santé publique. INRA Prod. Anim., 24, 199-204.

Chapitres de livres

  • Lees P., Toutain P.L. (2011) Pharmacokinetics, Distribution, Bioavailability, and Relationship to Antibiotic Residues. In: Chemical Analysis of Antibiotic Residues in Food. W. Jian, J. D. MacNeil and J. F. Kay, Wiley-Blackwell.
  • Riviere J.E., Toutain P.L. (2011) Simultaneous Pharmacokinetic–Pharmacodynamic Modeling. In: Comparative Pharmacokinetics: Principles, Techniques and Applications. J. Riviere, Wiley-Blackwell.

Communiqués de presse

  • Les antibiotiques, traiter le plus tôt est le mieux ! In: INRA SP ed, En direct des labos: INRA; 2011 ()
  • Early treatment with antibiotics is best! In: INRA SP ed, En direct des labos: INRA; 2011 ()
  • Les antibiotiques, traiter le plus tôt est le mieux ! INRA Fiche de Presse Info, 16/02/2011. ()

Conférences

2011

  • Dupouy V., Bibbal D., Arpaillange N., Brugere H., Oswald E., Toutain P.L., Bousquet-Melou A. (2011) Prevalence and molecular characterization of CTX-M-producing Escherichia coli isolates from wastewaters of a couple slaughterhouse/wastewater treatment plant. 4th Symposium on Antimicrobial Resistance in Animals and the Environment, INRA. Tours, France, 27-29 June 2011.
  • Ferran A., Toutain P.L., Bousquet-Melou A. (2011) Effects of early versus late treatments by marbofloxacin in a mouse-model of Pasteurella multocida pulmonary infection. 4th Symposium on Antimicrobial Resistance in Animals and the Environment, INRA. Tours, France, 27-29 June 2011.

2010

  • AuthiéE., Garcia P., Popot M.A., ToutainP.L., DoucetM.Y. (2010) Effect of an endurance-like exercise on the disposition and detection time of phenylbutazone and dexamethasone in the horse: application to medication control, Equine Vet J, 42(3): 240-247. [IF 2009=1.837; IF 5-Year=2.310; VETERINARY SCIENCES, Q1]
  • Cattiaux P., Chafai D., Motsch S. (2010) Asymptotic analysis and diffusion limit of the Persistent Turning Walker Model, Asymptotic Analysis, 67(1-2): 17-31.
  • ChafaïD., Malrieu F. (2010) On fine properties of mixtures with respect to concentration of measure and Sobolev type inequalities, Ann. Inst. Henri Poincare,46, 72-96.(* : membre de l’équipe jusqu’en septembre 2009)
  • ChafaïD., Malrieu F. , Paroux K. (2010) On the long time behaviour of the TCP window size process, Stoch. P
  • Kesteman A.S., Perrin-Guyomard A., Laurentie M., Sanders P., Toutain P.L., Bousquet-MelouA. (2010) Emergence of resistant Klebsiella pneumoniae in the intestinal tract during successful treatment of Klebsiella pneumoniae lung infection in rats, Antimicrob Agents Chemother, 54(7): 2960-4. [IF 2009=4.802; IF 5-Year=4.819; PHARMACOLOGY & PHARMACY, Q1]
  • Schmitt A., Gladieff L., Laffont C.M., Evrard A., Boyer J.C., Lansiaux A., Bobin-Dubigeon C., Etienne-Grimaldi M.C, Boisdron-Celle M., Mousseau M., Pinguet F., Floquet A., Billaud E.M., Durdux C., Le Guellec C., Mazières J., Lafont T., Ollivier F., Concordet D., Chatelut E. (2010) Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic Exposure, J. Clin. Oncol. 28(30): 4568-4574. [IF 2009=17.763; IF 5-Year=15.969; ONCOLOGY, Q1]
  • Toutain P.L. (2010) How to extrapolate a withdrawal time from an EHSLC published detection time: a Monte Carlo simulation appraisal, Equine Vet J, 42(3): 248-254. [IF 2009=1.837; IF 5-Year=2.310; VETERINARY SCIENCES, Q1]
  • Toutain P.L. (2010) Veterinary medicines and competition animals: the question of medication versus doping control, Handb Exp Pharmacol (199): 315-39.
  • Toutain P.L., Ferran A. and Bousquet-Melou A. (2010) Species differences in pharmacokinetics and pharmacodynamics, Handb Exp Pharmacol (199): 19-48.

Chapitres de livres

  • Bordenave C., Caputo P. , Chafaï D. (2010) Spectrum of large random reversible Markov chains -heavy-tailed weights on the complete graph.
  • Toutain P.L. (2010) Veterinary medicines and competition animals: the question of medication versus doping control. Handbook of Experimental Pharmacology. Comparative and Veterinary Pharmacology. F. Cunningham, J. Elliott and P. Lees. Berlin, Springer: 315-39.
  • Toutain P.L., Ferran A. and Bousquet-Melou A. (2010) Species differences in pharmacokinetics and pharmacodynamics. Handbook of Experimental Pharmacology. Comparative and Veterinary Pharmacology. F. Cunningham, J. Elliott and P. Lees. Berlin, Springer: 19-48.
  • Toutain P.L., Guatteo R., Guémené D., Latouche K., Leterrier C., Mounier L., Prunier A. and Terlouw C. (2010) Chapitre 5. Solutions pour limiter la douleur chez les animaux d'élevage. Douleurs animales : les identifier, les comprendre, les limiter chez les animaux d'élevage. Expertise scientifique collective. P. Le Neindre, R. Guatteo, D. Guémené et al. Paris, France, INRA.

 Articles de tranfert/vulgarisation

  • Bousquet-Melou A. (2010) Quelle voie d'administration des antibiotiques choisir ? Bulletin des GTV. Paris, Société Nationale des Groupements Techniques Vétérinaires: 49-53.
  • Ferran A., Toutain P.L. and Bousquet-Melou A. (2010) "Vite, fort, longtemps", est-ce toujours d'actualité en antibiothérapie? Bulletin des GTV. Paris, Société Nationale des Groupements Techniques Vétérinaires: 55-59.
  • Latieule S., Bartoli F., Bulteel L., Olivier H., Louis P. and Toutain P.L. (2010) L'image du générique. STP Pharma Pratiques. 20: 263-274.
  • Toutain P.L. (2010) Antibiothérapie prudente en élevage : avantages possibles de la métaphylaxie en termes d'antibiorésistance. Journée sur l'antibiorésistance en santé animale. Maisons Alfort, ANSES: 22.

Conférences

2012

  • Bousquet-Melou A., Laffont C.M., Toutain P.L. Licking behaviour affects the disposition of macrocyclic lactone pour-on formulations in cattle.European Association for Veterinary Pharmacology and Therapeutics. 12th International Congress, Noordwijkerhout, 2012.
  • Bousquet-Melou A., A. Cloeckaert. Emergence et diffusion de résistances aux antibiotiques en lien avec leur usage en élevage.Rencontre « Anti-infectieux en élevage : Recherches et alternatives durables » - Salon International de l’Agriculture (stand INRA), Février 2012
  • Laffont C. (2012) How population PK/PD improves the evaluation and clinical use of veterinary drugs. Keynote. In: 12th International Congress of the European Association for Veterinary Pharmacology and Toxicology. EAVPT ed. Noordwijkerhout, NL, 8-12 July 2012.
  • Toutain P.L. (2012) Similarities and differences. The challenge of implementing lessons learned in human medicine into an animal health environment: companion animals vs.food-producing animals. In: 6th International Conference on Antimicrobial Agents in Veterinary Medicine. AAVM ed. Washington, DC, USA, 23-26 October 2012.31
  • Toutain P.L. (2012) Are we over-rating the risk of low-dose drug exposure on the selection of resistant straints? In: 6th International Conference on Antimicrobial Agents in Veterinary Medicine. AAVM ed. Washington, DC, USA, 23-26 October 2012.33
  • Toutain P.L. (2012) What are the public health issues that practitioners have to consider to enforce a sustainable use of antibiotics? In: 12th International Congress of the European Association for Veterinary Pharmacology and Toxicology. EAVPT ed. Noordwijkerhout, NL, 8-12 July 2012.Keynote
  • Toutain P.L. (2012) Antibiotic dosage regimen for a sustainable use of antibiotics in veterinary medicine. In: 12th International Congress of the European Association for Veterinary Pharmacology and Toxicology. EAVPT ed. Noordwijkerhout, NL, 8-12 July 2012.Workshop
  • Toutain P.L. (2012) PK/PD models for drug administrations. In: 19th Conference of Racing Analysts and Veterinarians - Animal welfare and anti-doping science week. ICRAV ed. Philadelphia, USA, 15-21 September 2012.

2010

  • Bousquet-Melou A. (2010) Antibiothérapie : Quelle voie choisir ? Journées nationales des GTV : Antibiothérapie : Santé animale et santé publique, SNGTV. Lille, France, 26-28 May, 2010.
  • Bousquet-Melou A. (2010) Does the approval of old generic antimicrobials increase the risk of selecting for resistant microbial strains? Bioequivalence workshop, AAVPT/ECVCP. Potomac, Md, USA, 27-30 June 2010.
  • Bousquet-Melou A. (2010) Licking concerns and bioequivalence determinations. Bioequivalence workshop, AAVPT/ECVCP. Potomac, Md, USA, 27-30 June 2010.
  • Bousquet-Melou A., Ferran A.A. and Toutain P.L. (2010) La détermination d'un schéma thérapeutique pour un antibiotique. Journées nationales des GTV : Antibiothérapie : Santé animale et santé publique, SNGTV. Lille, France, 26-28 May, 2010.
  • Bousquet-Mélou A., Ferran A.A. and Toutain P.L. (2010) Metaphylaxis and prophylaxis in veterinary antimicrobial therapy. Fifth International Conference on Antimicrobial Agents in Veterinary Medicine. Tel-Aviv, Israel, 11-14 May 2010.
  • Concordet D. (2010) What is the experimental unit in premix bioequivalence? Bioequivalence workshop, AAVPT/ECVCP. Potomac, Md, USA, 27-30 June 2010.
  • Ferran A.A., Toutain P.L. and Bousquet-Melou A. (2010) Effects of early versus late treatments by marbofloxacin in a mouse-model of Pasteurella multocida pulmonary infection. Fifth International Conference on Antimicrobial Agents in Veterinary Medicine. Tel-Aviv, Israel, 11-15 May 2010.
  • Ferran A.A., Toutain P.L. and Bousquet-Melou A. (2010) "Vite, fort, longtemps", est-ce toujours d'actualité ? Journées nationales des GTV : Antibiothérapie : Santé animale et santé publique, SNGTV. Lille, France, 26-28 May, 2010.
  • Khachman D., Laffont C. and Concordet D. (2010) You have problems to interpret VPS? try VIPER! Population Approach Group in Europe (PAGE). Berlin, Germany, 8-11 June 2010.
  • Paepe D., Lefebvre H.P., Concordet D., van Hoek I., Smets P., Croubels S. and Daminet S. (2010) Limited sampling strategies to estimate glomerular filtration rate in cats with low, normal and high glomerular filtration rates. ACVIM, Journal of Veterinary Internal Medicine, WILEY-BLACKWELL PUBLISHING, INC., May-Jun.
  • Toutain P.L. (2010) Amoxicillin breakpoint for swine: evidence for the need to revise and clinical consequences of using the current, inappropriate human-derived values. FDA Drug Resistance Seminar. Rockville, MD, USA, Center for Veterinary Medicine, 1 September 2010.
  • Toutain P.L. (2010) Clinical trial study design: challenging conventional non-inferiority study design paradigms. FDA Drug Resistance Seminar. Rockville, MD, USA, Center for Veterinary Medicine, 1 September 2010.
  • Toutain P.L. (2010) The consequences of the generics market on antibiotic consumption and the spread of antibiotic resistance: facts and hypotheses. Fifth International Conference on Antimicrobial Agents in Veterinary Medicine. Tel-Aviv, Israel, 11-14 May 2010.
  • Toutain P.L. (2010) Does price encourage the usage of old and poorly effective-but cheaper antibiotics. FDA Drug Resistance Seminar. Rockville, MD, USA, Center for Veterinary Medicine, 1 September 2010.
  • Toutain P.L. (2010) How to use irrelevant plasma and urine drug concentrations in doping control in the FEI. FEI Congress on NSAID usage and medication in the equine athlete. Lausanne, Switzerland, FEI, 16 & 17 August 2010.
  • Toutain P.L. (2010) Predictive value of PK/PD drug modelling: application to analgesic drugs. Official satellite Symposium of the 13th World Congress on Pain. Montreal, Canada, Pain and pain management in non-human species Special interest group, August, 29, 2010.
  • Toutain P.L. (2010) Prudent use of antimicrobials: the advantage of metaphylaxis. FDA Drug Resistance Seminar. Rockville, MD, USA, Center for Veterinary Medicine, 1 September 2010.